In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).
|Original language||English (US)|
|Number of pages||2|
|State||Published - May 22 2014|
ASJC Scopus subject areas
- Cell Biology